Search research articles
Contact Us
Filters
Showing results (31-40 of 448) with videos related to
Page
of 45
Sort By:
Cancer Research
|
July 19, 2002
Molecular effects of the herbal compound PC-SPES: identification of activity pathways in prostate carcinoma
Michael Bonham, Hugh Arnold, Bruce Montgomery, et al.
Bioinformatics (Oxford, England)
|
April 6, 2010
Supervised normalization of microarrays
Brigham H Mecham, Peter S Nelson, John D Storey
Urology
|
May 27, 2008
Prostate tissue androgens: history and current clinical relevance
Leonard S Marks, Elahe A Mostaghel, Peter S Nelson
Expert Review of Molecular Diagnostics
|
July 16, 2010
Genomic predictors of prostate cancer therapy outcomes
Daniel J Lewinshtein, Christopher R Porter, Peter S Nelson
Molecular and Cellular Endocrinology
|
March 29, 2012
Androgen action and metabolism in prostate cancer
Sean M Green, Elahe A Mostaghel, Peter S Nelson
Nucleic Acids Research
|
December 26, 2001
The human (PEDB) and mouse (mPEDB) Prostate Expression Databases
Peter S Nelson, Colin Pritchard, Denise Abbott, et al.
BJU International
|
September 3, 2011
Incidence of second malignancies after external beam radiotherapy for clinical stage I testicular seminoma
Dan Lewinshtein, Roman Gulati, Peter S Nelson, et al.
Cancer Research
|
October 14, 2010
Intraprostatic steroidogenic enzymes - letter
Elahe Mostaghel, Peter S Nelson, Colleen Nelson, et al.
Bioinformatics (Oxford, England)
|
June 8, 2004
Bayesian integrated functional analysis of microarray data
Madhuchhanda Bhattacharjee, Colin C Pritchard, Peter S Nelson, et al.
Nature Clinical Practice. Urology
|
February 10, 2009
Androgen deprivation therapy: progress in understanding mechanisms of resistance and optimizing androgen depletion
William P Harris, Elahe A Mostaghel, Peter S Nelson, et al.
Page
of 45
Search research articles
Search
Showing results (31-40 of 448) with videos related to
Sort By:
Page
of 45
Cancer Research
|
July 19, 2002
Molecular effects of the herbal compound PC-SPES: identification of activity pathways in prostate carcinoma
Michael Bonham, Hugh Arnold, Bruce Montgomery, et al.
Bioinformatics (Oxford, England)
|
April 6, 2010
Supervised normalization of microarrays
Brigham H Mecham, Peter S Nelson, John D Storey
Urology
|
May 27, 2008
Prostate tissue androgens: history and current clinical relevance
Leonard S Marks, Elahe A Mostaghel, Peter S Nelson
Expert Review of Molecular Diagnostics
|
July 16, 2010
Genomic predictors of prostate cancer therapy outcomes
Daniel J Lewinshtein, Christopher R Porter, Peter S Nelson
Molecular and Cellular Endocrinology
|
March 29, 2012
Androgen action and metabolism in prostate cancer
Sean M Green, Elahe A Mostaghel, Peter S Nelson
Nucleic Acids Research
|
December 26, 2001
The human (PEDB) and mouse (mPEDB) Prostate Expression Databases
Peter S Nelson, Colin Pritchard, Denise Abbott, et al.
BJU International
|
September 3, 2011
Incidence of second malignancies after external beam radiotherapy for clinical stage I testicular seminoma
Dan Lewinshtein, Roman Gulati, Peter S Nelson, et al.
Cancer Research
|
October 14, 2010
Intraprostatic steroidogenic enzymes - letter
Elahe Mostaghel, Peter S Nelson, Colleen Nelson, et al.
Bioinformatics (Oxford, England)
|
June 8, 2004
Bayesian integrated functional analysis of microarray data
Madhuchhanda Bhattacharjee, Colin C Pritchard, Peter S Nelson, et al.
Nature Clinical Practice. Urology
|
February 10, 2009
Androgen deprivation therapy: progress in understanding mechanisms of resistance and optimizing androgen depletion
William P Harris, Elahe A Mostaghel, Peter S Nelson, et al.
Page
of 45